Please wait while the formulary information is being retrieved.
Drug overview for ALYMSYS (bevacizumab-maly):
Generic name: bevacizumab-maly (BE-va-SIZ-oo-mab)
Drug class: Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody
Therapeutic class: Antineoplastics
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: bevacizumab-maly (BE-va-SIZ-oo-mab)
Drug class: Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody
Therapeutic class: Antineoplastics
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
ALYMSYS 100 MG/4 ML VIAL
ALYMSYS 400 MG/16 ML VIAL
The following indications for ALYMSYS (bevacizumab-maly) have been approved by the FDA:
Indications:
Carcinoma of cervix
Epithelial ovarian cancer
Glioblastoma multiforme
Metastatic colorectal cancer
Metastatic renal cell carcinoma
Nonsquamous non-small cell lung cancer
Professional Synonyms:
Carcinoma of ovary
Cervical carcinoma cancer
Cervical carcinoma
Epithelial carcinoma of ovary
Epithelial ovarian carcinoma
Grade IV astrocytoma
Malignant epithelial neoplasm of ovary
Metastatic carcinoma of kidney
Metastatic Grawitz tumor
Metastatic hypernephroid carcinoma
Metastatic hypernephroma
Metastatic kidney adenocarcinoma
Metastatic nephroid carcinoma
Metastatic renal adenocarcinoma
Metastatic renal carcinoma
Metastatic renal cell adenocarcinoma
Metastatic renal cell cancer
Nonsquamous NSCLC
Ovarian carcinoma
Indications:
Carcinoma of cervix
Epithelial ovarian cancer
Glioblastoma multiforme
Metastatic colorectal cancer
Metastatic renal cell carcinoma
Nonsquamous non-small cell lung cancer
Professional Synonyms:
Carcinoma of ovary
Cervical carcinoma cancer
Cervical carcinoma
Epithelial carcinoma of ovary
Epithelial ovarian carcinoma
Grade IV astrocytoma
Malignant epithelial neoplasm of ovary
Metastatic carcinoma of kidney
Metastatic Grawitz tumor
Metastatic hypernephroid carcinoma
Metastatic hypernephroma
Metastatic kidney adenocarcinoma
Metastatic nephroid carcinoma
Metastatic renal adenocarcinoma
Metastatic renal carcinoma
Metastatic renal cell adenocarcinoma
Metastatic renal cell cancer
Nonsquamous NSCLC
Ovarian carcinoma
The following dosing information is available for ALYMSYS (bevacizumab-maly):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ALYMSYS (bevacizumab-maly):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for ALYMSYS (bevacizumab-maly):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 12 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Abnormal vaginal bleeding |
| Alveolar hemorrhage |
| Gastrointestinal fistula |
| Gastrointestinal hemorrhage |
| Gastrointestinal perforation |
| Intracerebral hemorrhage |
| Lactation |
| Necrotizing fasciitis |
| Nephrotic syndrome |
| New fistula formation involving an internal organ |
| Posterior reversible encephalopathy syndrome |
| Tracheoesophageal fistula |
There are 15 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Acute myocardial infarction |
| Angina |
| Chemotherapy-induced neutropenia |
| Chronic heart failure |
| Erosive esophagitis |
| Female hypogonadism |
| Hypertension |
| Impaired wound healing |
| Invasive surgical procedure |
| Neutropenic disorder |
| Pregnancy |
| Proteinuria |
| Surgical wound dehiscence |
| Thromboembolic disorder |
| Transient cerebral ischemia |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Secondary ovarian failure |
The following adverse reaction information is available for ALYMSYS (bevacizumab-maly):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 72 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dyspnea Exfoliative dermatitis Gastrointestinal hemorrhage Hyperbilirubinemia Hypertension Increased alanine transaminase Increased aspartate transaminase Leukopenia Neutropenic disorder Proteinuria Rectal bleeding Secondary ovarian failure Stomatitis Venous thrombosis |
Chest pain Colitis Deep venous thrombosis Dehydration Gastrointestinal ulcer Hypersensitivity drug reaction Hypomagnesemia Hyponatremia Hypotension Ileus Infection Kidney disease with reduction in glomerular filtration rate (GFr) Left ventricular failure Skin ulcer Syncope Thrombocytopenic disorder Thrombotic disorder |
| Rare/Very Rare |
|---|
|
Abnormal vaginal bleeding Acute arterial thromboembolism Acute myocardial infarction Acute occlusion of mesenteric vein Anaphylaxis Arterial aneurysm Arterial dissection Aseptic necrosis of jaw bone Bleeding esophageal varices Bloody vomit Cerebral ischemia Cerebrovascular accident Chronic heart failure Conjunctival hemorrhage Dissection of aorta Endophthalmitis Gastrointestinal fistula Gastrointestinal perforation Gastrojejunal ulcer Hemoptysis Hemorrhage Hypertensive crisis Hypokalemia Impaired wound healing Intestinal ischemic necrosis Intracerebral hemorrhage Nasal septal perforation Necrotizing fasciitis Nephrotic syndrome New fistula formation involving an internal organ Pancytopenia Perforation of gallbladder Polyserositis Posterior reversible encephalopathy syndrome Pulmonary hemorrhage Pulmonary hypertension Retinal detachment Surgical wound dehiscence Thrombotic thrombocytopenic purpura Tracheoesophageal fistula Transient cerebral ischemia |
There are 40 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Anorexia Arthralgia Back pain Diarrhea Dizziness Dry skin Dysgeusia Epistaxis Eye tearing Fatigue General weakness Headache disorder Myalgia Nausea Peripheral sensory neuropathy Rhinitis Upper respiratory infection Vomiting |
Alopecia Angina Constipation Dysarthria Dyspepsia Hemorrhoids Hyperhidrosis Lymphopenia Muscle weakness Nasal passage irritation Pain Pelvic pain Rectal pain Rhinorrhea Voice change Weight loss Xerostomia |
| Rare/Very Rare |
|---|
|
Blurred vision Ocular inflammation Vitreous floater Wheezing |
The following precautions are available for ALYMSYS (bevacizumab-maly):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
Contraindicated
Absolute contraindication. (Human data usually available to support recommendations.) This drug should not be given to breast feeding mothers.
Contraindicated
Absolute contraindication. (Human data usually available to support recommendations.) This drug should not be given to breast feeding mothers.
| Drug Name | Excretion Potential | Effect on Infant | Notes |
|---|---|---|---|
| Bevacizumab | Unknown. It is unknown whether the drug is excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Insuff data; mfr recs avoid during breastfeeding and 6 mo after last dose |
No enhanced Geriatric Use information available for this drug.
Precaution Exists
Geriatric management or monitoring precaution exists.
Precaution Exists
Geriatric management or monitoring precaution exists.
| Drug Name | Narrative | REN | HEP | CARDIO | NEURO | PULM | ENDO |
|---|---|---|---|---|---|---|---|
| Bevacizumab | General-Increased risk for severe side effects, including sepsis, deep thrombophlebitis, arterial thromboembolism, hypertension, hypotension, edema, MI, GI hemorrhage. | Y | N | Y | Y | Y | N |
The following prioritized warning is available for ALYMSYS (bevacizumab-maly):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ALYMSYS (bevacizumab-maly)'s list of indications:
| Carcinoma of cervix | |
| C53 | Malignant neoplasm of cervix uteri |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| Epithelial ovarian cancer | |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| Glioblastoma multiforme | |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
| Metastatic colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| Metastatic renal cell carcinoma | |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| Nonsquamous non-small cell lung cancer | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
Formulary Reference Tool